Key Findings

Three Escherichia coli clinical isolates with reduced susceptibility to cefepime were found to produce novel variants of CMY-2 beta-lactamase, CMY-33 and CMY-44, which have deletions in the H-10 helix leading to increased MICs of cefepime.